Description and Brand Names
Información sobre medicamentos proporcionada por: IBM Micromedex
US Brand Name
Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Myelofibrosis is a life-threatening bone marrow problem which is manifested by the following symptoms: enlarged spleen (splenomegaly), severe itching, fever, night sweats, weight loss, bone pain, or unusual tiredness or weakness. It is also used to treat polycythemia vera in patients who have been previously treated with hydroxyurea that did not work well.
Ruxolitinib is also used to treat acute graft-versus-host disease (GVHD) in patients who have been treated with other medicines (eg, steroids) that did not work well.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms: